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Background: Adoptive transfer of CMV-specific T cells has shown promising results in preventing pathological effects
caused by opportunistic CMV infection in immunocompromised patients following allogeneic hematopoietic stem cell
transplantation. The majority of studies have used steady-state leukapheresis for CMV-reactive product manufacture, a
collection obtained prior to or months after G-CSF mobilization, but the procurement of this additional sample is often
not available in the unrelated donor setting. If the cellular product for adoptive immunotherapy could be generated
from the same G-CSF mobilized collection, the problems associated with the additional harvest could be overcome.
Despite the tolerogenic effects associated with G-CSF mobilization, recent studies described that CMV-primed T cells
generated from mobilized donors remain functional.
Methods: MHC-multimers are potent tools that allow the rapid production of antigen-specific CTLs. Therefore, in the
present study we have assessed the feasibility and efficacy of CMV-specific CTL manufacture from G-CSF mobilized
apheresis using MHC-multimers.
Results: CMV-specific CTLs can be efficiently isolated from G-CSF mobilized samples with Streptamers and are able to
express activation markers and produce cytokines in response to antigenic stimulation. However, this anti-viral functionality
is moderately reduced when compared to non-mobilized products.
Conclusions: The translation of Streptamer technology for the isolation of anti-viral CTLs from G-CSF mobilized PBMCs
into clinical practice would widen the number of patients that could benefit from this therapeutic strategy, although our
results need to be taken into consideration before the infusion of antigen-specific T cells obtained from G-CSF mobilized
samples.
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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is usually followed by an immunosuppression
period during which patients are susceptible to opportun-
istic infections, including human cytomegalovirus (CMV)
as one of the most common viral-infections [1]. Although
pharmacological treatment is routinely used prophylac-
tically or pre-emptively to avoid reactivation or primary
infection, anti-viral drugs still have some limitations
since they are associated with both toxicity and delayed
immune reconstitution [2, 3]. It is widely accepted that
CMV-specific cytotoxic T lymphocytes are essential to
control virus-related complications after allo-HSCT [4].
Therefore the adoptive transfer of antigen-specific T
cells after allo-HSCT has been investigated, showing
promising results [5].
The majority of studies that generated virus-specific T
cells have used non-mobilized peripheral blood mono-
nuclear cells (PBMCs) isolated from an additional leu-
kapheresis collection from the original allo-HSCT
donor, different to that of the peripheral blood stem cell
(PBSCs) collection performed after granulocyte-colony
stimulating factor (G-CSF; Filgrastim) treatment. This
additional leukapheresis harvest, apart from increasing
the cost of the procedure and the discomfort caused to
the donor, can be difficult to obtain in the unrelated
donor setting where donor refusal or logistical and
scheduling difficulties can prevent collection [6–8].
Manufacture of virus-specific T cells from the original
G-CSF mobilized collection could potentially overcome
the difficulties associated with procurement of a second
apheresis.
However, G-CSF administration has been associated
with a tolerogenic T cell phenotype; it promotes regula-
tory T cells that produce the anti-inflammatory cytokine
IL-10, induces a polarization towards T helper cell type
2 (Th2) differentiation and while inhibiting Th cell type
1 (Th1) differentiation [9, 10] and decreasing the expres-
sion of genes associated with cytotoxicity, antigen pres-
entation and graft-versus-host disease [11].
Streptamer technology avoids the strict requirements
associated with advanced therapy medicinal product
(ATMP) manufacture, due to minimal manipulation of
direct selection [12] and holds great promise in the un-
related donor setting, widening the clinical application
of this fast and simple methodology [13–15]. In this
present study we evaluated the feasibility of generating
therapeutic CMV-reactive cytotoxic T cells (CTLs)
using Streptamers from G-CSF treated donor samples,
and were able to show that CMV-specific T cells dir-
ectly selected from G-CSF mobilized samples are highly
functional, although their potential is slightly reduced
when compared to non-mobilized CMV-specific CTLs
(CMV-CTLs).Methods
Donor population and ethical statement
This descriptive study was approved by the Institutional
Review Board at Complejo Hospitalario de Navarra (CHN),
and all donors gave written informed consent in accord-
ance with the Declaration of Helsinki prior to enrolment.
All samples were obtained from CMV-seropositive healthy
donors who carried the HLA-A*02:01 allele. Serological
analysis for CMV was obtained from the Microbiology Ser-
vice of the CHN and HLA-I typing was done in the Im-
munology Unit of the CHN.G-CSF mobilized and non-mobilized donor sample
collection and preparation
Filgrastim treated PBMCs (n = 3) were obtained from
leukapheresis collected from healthy donors who re-
ceived 10 μg/kg/day of recombinant G-CSF (Sandoz
Biopharmaceuticals, Paris, France) every 12 h starting
five days before collection. Leukapheresis were per-
formed with a COBE Spectra continuous flow blood
cell separator (COBE Spectra apheresis system, Caridian
BCT, Lakewood, CO, USA). Cell products anticoagulated
with acid citrate dextrose were collected with a 1.1 ml/
min flux in a 500 ml container, and an aliquot of 1 ml was
taken from the apheresis collection to perform the assays.
Non-mobilized PBMCs (n = 3) were isolated from buffy
coat samples anticoagulated with citrate phosphate dex-
trose obtained from anonymized healthy donors in the
Blood and Tissue Bank of Navarra (BSTN). PBMCs were
isolated by Ficoll-Paque density gradient centrifugation
(GE Healthcare Bio-Sciences, Uppsala, Sweden), counted
in a Neubauer Hemocytometer using 0.4 % trypan blue
staining (Sigma-Aldrich, St. Louis, MO) and cells were re-
suspended in RPMI 1640 Medium (Life Technologies,
Paisley, UK) supplemented with 10 % human AB serum
(Lonza, Basel, Switzerland). Approximately 30 × 106
freshly isolated PBMCs were cryopreserved for later use as
feeders in functional assays. Briefly, PBMCs were mixed
with fetal bovine serum (Lonza) containing 20 %
dimethylsulphoxide (WakChemie, Steinbach, Germany),
at a 1:1 ratio.Myeloid precursor removal by plastic adherence
In order to minimize the presence of non-specific cells
in the cellular product, the sample was enriched for
CTLs by a plastic adherence process [16]. In brief,
2.25 × 108 cells were plated in sterile 225 cm2 A/N
flasks with CellBIND Surface (Corning, Corning, NY)
at 0.5 × 106 cells/ml in X-VIVO 15 Serum-free cell
medium w/o supplements (Lonza). Cells were incu-
bated for 1 h at 37 °C and 5 % CO2. Non-adherent
cells were carefully collected by aspiration to avoid the
disruption of adherent myeloid cellular populations and
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(dPBS; Sigma-Aldrich) before quantification.
CMV-specific CTL isolation with Streptamer technology
Two different technical approximations were performed
in order to obtain a cellular product of anti-CMV thera-
peutic T cells; in the first one, CMV-specific T cells were
isolated and subsequently expanded in order to obtain
enough cells to perform functional assays. In the second
approach, the PBMC sample was first enriched in CMV-
CTLs by antigen stimulation before their isolation was
carried out.
Isolation of CMV-specific CTLs by multimer staining and
subsequent in vitro expansion
For 50 × 106 non-adherent PBMCs, 3.75 μg of Streptamer
(ST) Magnetic Beads and 5 μg of ST MHC class I (HLA-
A*02:01/CMVpp65-NLVPMVATV Streptamer; both from
IBA GmbH, Göttigen, Germany) were incubated over-
night at 4 °C in the dark to generate the ST-magnetic bead
complex. This complex was added to the cell pellet and
incubated for 45 min at 4 °C in the dark. ST+ cells were
isolated using a Possel_ds selection program on the Auto-
MACS Pro separator (Miltenyi Biotec, Bergisch Gladbach,
Germany). ST was dissociated from the eluted cells with
1 mM D-biotin (IBA GmbH), or left bound to the cell in
order to compare the effect of constant binding of the
multimer to the TCR.
Following magnetic enrichment, up to 100.000 ST+
CMV-specific CTLs were co-cultured with 8 × 106 γ-
irradiated (30Gy) autologous PBMCs that were pre-loaded
with 10 μg/ml CMVpp65495–503 peptide (NLVPMVATV)
overnight (Proimmune, Oxford, UK). The expansion was
carried out in round bottom tissue culture tubes (Falcon
BD Biosciences) in RPMI 1640 supplemented with 10 %
human AB serum, 1 % penicillin/streptomycin (Lonza)
and 10 ng/ml of IL-7 and IL-15 (Miltenyi Biotec). Cells
were expanded over 21 days, culture medium was chan-
ged every 2 or 3 days and cells split when necessary.
Viable cell counts were performed every 2–3 days using
0.4 % trypan blue staining.
CMV-specific CTL isolation after enrichment during
expansion
Before automated CMV-specific CTL selection, the
number of specific T cells was increased by stimulating
all PBMCs with the CMVpp65495–503 peptide. Briefly, up
to 30 × 106 PBMCs were cultured in round bottom cul-
ture tubes in the presence of 10 μg/ml CMVpp65495–503
peptide and IL-7 and IL-15 as previously described, at a
concentration of 5 × 105 cells/ml.
After expansion, up to 1 × 108 cells were stained with
the ST-magnetic bead complex and ST+ cells were iso-
lated as previously described.Characterization of specificity and immunophenotype of
CMV-specific cells
To analyze the phenotype and purity of the fresh iso-
lated products and expanded cells, they were stained
with the ST-PE complex. Briefly, 0.75 μg of PE-labelled
Strep-Tactin and 0.5 μg of antigen-specific MHC I-Strep
(HLA-A*02:01/NLVPMVATV Streptamer) were incu-
bated during 45 min at 4 °C in the dark to form the ST-
PE complex. 0.2 μg of this reversible multimer were
added to 1 × 106 cells. The incubation was carried out
during 45 min at 4 °C in the dark and afterwards cells
were stained with, CD8-FITC (BioLegend, San Diego,
USA), CD3-PerCP, CD137-APC (Miltenyi Biotec), and
CD4-APC-Cy7 (BD Biosciences, San Jose, USA).
During the culture period, specificity and phenotype of
expanded cells were analyzed every 7 days by staining
with the ST-PE complex and monoclonal antibodies as
previously described, with the addition of CD69 PE-Cy7
and CD57 VioBlue (Miltenyi Biotec).
Furthermore, at the beginning and the end of the ex-
pansion the memory phenotype of the cells was analyzed
by staining with CD45RA-V450 and CCR7-PE-Cy7 (both
BD Biosciences) during 15 min at room temperature.
Analysis of cell-surface expression of activation markers
upon antigenic re-stimulation
Expanded CMV-CTLs cells were re-stimulated with ei-
ther CMVpp65495–503-loaded or untouched feeders, used
as CMV-stimulator or control feeders respectively, and
activation marker expression was analyzed.
Briefly, autologous PBMCs were thawed out to be used
as feeders and labelled with 1 μM carboxyfluorescein
diacetate succinimidyl ester (CFSE) to discriminate between
feeders and responder CMV-CTLs during flow cytometry
acquisition and analysis. Subsequently, they were plated
at 3 × 106 cells/ml, and loaded with 10 μg/ml
CMVpp65495–503 peptide to produce CMV-loaded
feeders, or left untouched as control feeders and incu-
bated overnight at 37 °C with 5 % CO2.
Expanded CMV-CTLs were re-stimulated with either
CMV-loaded or control feeders at a 2.5:1 feeder:responder
ratio, with 1 × 106 cells/well in 96 well plates. Samples
were incubated for 6 h and afterwards 500,000 cells were
stained with anti-human CD8-PerCP, CD137-APC, CD4-
APC-Cy7, and CD69-PE-Cy-7 monoclonal antibodies.
Evaluation of cytokine production in response to
re-stimulation with the antigen
To assess the effector activity of CMV-CTL by intracel-
lular cytokine staining, expanded cells were co-cultured
for 6 h with CMV-loaded or control feeders labelled
with CFSE at a 2.5:1 ratio, in the same way as for surface
activation marker expression analysis. The incubation
was done in the presence of 1 μg/ml anti-CD28 (BD
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Following the incubation, 1 × 106 cells were stained with
either PE-conjugated anti-human IFN-γ, IL-2, IL-10,
TNF-α, or Granzyme B (BD Biosciences) and with CD8-
PerCP and CD4-APC-Cy7 monoclonal antibodies, then
fixed and permeabilized (Intrastain; DakoCytomation,
Ely, UK), according to the manufacturer’s instructions.Flow cytometric analysis and isotype controls
All flow cytometry experiments consisted of five to
seven color panels, where a minimum of 50.000
CD3+ cells were acquired. CD3+ cells were defined
after gating viable lymphocyte population using the
Forward Scatter (FSC) versus Side Scatter (SSC)
dot-plot, and cell population percentages were derived
from the CD3+ cell gate, except for the memory T cell
phenotype that is derived from the CD3 + CD8 + ST+
CMV-CTL gate. Data were acquired on a FACSCanto II
flow cytometer (BD) and analyzed using FlowJo version 10
(TreeStar Inc., Ashland, OR, USA). Data were summa-
rized using descriptive statistics such as mean ± standard
deviations (SD).
For cytokine and activation marker staining controls,
mouse antibodies of matching isotype conjugated with
PE, APC or APC-Cy7 (BD Biosciences) were used.Results
CMV-CTL isolation from G-CSF mobilized and
non-mobilized samples
Streptamer technology was used to quantify and isolate
CMV-CTL from non-mobilized or G-CSF mobilized
PBMCs. The mean frequency of CD3 + CD8 + ST+ in
the G-CSF mobilized starting material was 1.56 % ± 2.42,
compared to 0.5 % ± 0.29 CD3 + CD8 + ST+ in non-
mobilized PBMCs. It is noteworthy to mention the high
variability between samples, probably due to inter-
individual variability because non-mobilized and G-CSF
mobilized samples were collected from different individ-
uals. CMV-CTLs were isolated from original samples
using Streptamer and the purity of the obtained product
was determined as the percentage of ST+ cells in the
product, whereas the yield was defined as the absolute
number of ST+ cells present in the positive fraction as a
proportion of the absolute number of ST+ cells in the
sample prior to isolation (Fig. 1a, 1b). In G-CSF mobilized
samples, a mean of 20.77 ± 7.83 × 106 PBMCs were used
for the isolation, and a cell product made of a mean of 6.5
± 3.97 × 104 cells with a mean purity of 75.27 % ± 33.15
and yield of 56.28 % ± 26.14 was obtained. From non-
mobilized samples, a mean of 37.39 ± 15.73 × 106 PBMCs
were used to obtain a cell product made of 7.58 ± 5.82 ×
104 CMV-CTL with a mean purity of 88.9 % ± 13.67 and
yield of 56.19 % ± 33.95.In vitro CMV-CTL expansion potential is weakened in G-CSF
mobilized samples
To increase the number of isolated CMV-specific T cells in
order to perform functional assays, cells dissociated from
the streptamer (Additional file 1: Figure S1) were cultured
during 21 days in the presence of CMV-loaded feeders and
homeostatic IL-7 and IL-15 cytokines. The proliferative
ability of cells obtained from G-CSF mobilized samples or
from steady state leukapheresis was evaluated (Fig. 2a). The
expansion potential of CMV-CTL generated from G-CSF
mobilized PBMCs revealed amean fold expansion of 13.77 ±
10.10, obtaining 1.02 ± 0.36 × 106 CMV-CTLs after expan-
sion. G-CSF mobilized CMV-CTL showed a reduced ability
when compared to non-mobilized CMV-CTL (mean fold ex-
pansion: 263.75 ± 192.58), where 25 ± 33.69 × 106 CMV-
CTLwere obtained following expansion.
CMV-CTLs express the TCR that specifically recognizes the
CMVpp65495–503 peptide
Cells were phenotypically characterized during expan-
sion by staining with T cell subset markers, Streptamer,
and activation markers. Before starting the expansion,
the cellular products isolated from G-CSF mobilized
PBMCs were predominantly CD3 + CD8+ (77.90 % ±
31.17), and were contaminated with a high percentage of
CD3 + CD4+ (16.00 % ± 22.80). Following 21 day culture,
expanded cells showed an elevated CD3 + CD8+ T cell
population (83.63 % ± 45.08) and a reduced CD3 + CD4+
T cell population (14.49 % ± 19.71). In comparison,
streptamer isolated cells obtained from non-mobilized
PBMCs, prior to culture were 92.38 % ± 11.88 CD3 +
CD8+ and 1.96 % ± 1.21 CD3 + CD4+. Following expan-
sion mean proportion of CD3 + CD8+ and CD3 + CD4+
was 97.67 % ± 1.72 and 1.04 % ± 1.46, respectively.
CMVpp65495–503-specific TCR expression was analyzed
during the expansion (Fig. 2b) and internalization of
TCR complex could be observed using streptamer stain-
ing after the CMV-loaded feeder addition. The specific
TCR was re-expressed from day 7 and expression was
maintained until the end of the culture period. After
21 day expansion, the proportion of CD3 +CD8 + ST+ in
G-CSF mobilized cells was 75.4 % ± 26.69, and in non-
mobilized CMV-CTLs the frequency was 98.17 % ± 2.34.
CD137 and CD69 activation marker expression was
analyzed throughout the 21 day culture period (Fig. 2c);
CD137 expression was undetectable from the beginning
of the expansion and CD69 was heterogeneously and
unpredictably changed during the culture, for both G-
CSF mobilized and non-mobilized samples.
G-CSF mobilized CMV-CTL evolve towards a terminally
differentiated phenotype during culture
Senescence of expanded cells was investigated during
the culture period by CD57 expression analysis (Fig. 3a)
Fig. 1 CMV-CTL isolation by MHC-Streptamers. CMV-CTLs, that specifically recognize the CMVpp65495–503 peptide of the CMV, were sorted using
ST from G-CSF mobilized (n = 3) and non-mobilized (n = 3) donor samples. (a) Mean yield and purity of ST+ cell selection process from original
G-CSF mobilized and non-mobilized PBMCs. (b) Representative figure of CD3 + CD8 + ST+ cell isolation. ST expression is represented in resting
PBMCs and in the positive fraction. Displayed cells were previously gated on CD3+ T cells
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At the beginning of the expansion, mean CD57 expression
was 9.72 % ± 7.75 and 9.50 % ± 10.85 in G-CSF mobilized
and non-mobilized CMV-CTL, respectively. In compari-
son, after culture mean CD57 expression increased to
52.06 % ± 27.52 in the mobilized CMV-CTL product, and
to 81.15 % ± 3.94 in non-mobilized samples.
Memory phenotype of CMV-CTL before isolation, in
the positive fraction of ST+ cell products and after expan-
sion was analyzed by staining with CD45RA and CCR7
markers (Fig. 3b, c), and memory subpopulations defined
as follows: naïve T cells (TN, CD45RA+CCR7+), central
memory T cells (TCM, CD45RA-CCR7+), effector memory
T cells (TEM, CD45RA-CCR7-), and terminally differenti-
ated effector memory T cells (TEMRA, CD45RA+CCR7-).
CMV-CTL obtained from both G-CSF mobilized and non-
mobilized PBMCs were predominantly TEM with a consid-
erable TEMRA population (Table 1). Memory phenotype was
not notably modified when comparing cells before and after
isolation or at the end of the expansion period.
Expanded CMV-CTL express activation markers and
produce pro-inflammatory cytokines and granzyme B
After culture, the effector functional capacity of expanded
CMV-CTL was assessed by quantifying activation marker
expression and cytokine production upon re-stimulation
with the CMVpp65495–503 peptide.In G-CSF mobilized CMV-CTL, 73.05 % ± 17.61 cells
re-expressed CD137 activation marker after antigenic re-
challenge, and 90.50 % ± 12.16 were CD69+. These values
were similar to the expression observed in non-mobilized
CMV-CTLs (CD137+, 67.67 % ± 8.10; CD69+, 93.53 % ±
5.58) (Fig. 4a, b).
Intracellular cytokine staining following antigenic re-
challenge illustrated that CMV-CTL generated from
both mobilized and non-mobilized PBMCs were able to
secrete pro-inflammatory cytokines and granzyme B
(Fig. 4c, d). The secretion cytokine pattern in G-CSF
mobilized and non-mobilized CMV-CTLs was similar;
G-CSF mobilized CMV-CTLs produced high levels of
IFN-γ (82.10 % ± 19.86) and granzyme B (53.67 % ±
21.83). A lower percentage produced TNF-α (7.62 % ±
1.05) and IL-2 (1.44 % ± 0.84), with undetectable levels
of IL-10 anti-inflammatory cytokine production. How-
ever, the frequency of cytokine secreting cells was
slightly reduced when compared to that observed in
non-mobilized cells (96.27 % ± 1.57 IFN-γ+, 79.30 % ±
22.00 granzyme B+, 38.83 % ± 14.06 TNF-α+, 4.84 % ±
1.75 IL-2+ and undetectable levels of IL-10).
Functional CMV-CTL can be manufactured by Streptamer
isolation after previous antigen-specific cell enrichment
A different approach for CMV-specific T cell product
generation was accordingly assessed, from both mobilized
Fig. 2 In vitro expansion of isolated CMV-CTL and proliferative capacity of expanded cells. CMV-CTL obtained from G-CSF mobilized (n = 3) and
non-mobilized (n = 3) samples were expanded in vitro during 21 days co-cultured with irradiated CMV-loaded feeders and homeostatic cytokines.
Viable cells were counted every 2–3 days and fold expansion was calculated related to the cells at the beginning of the culture. Represented
percentages are obtained from CD3+ T cell gate. (a) Mean fold expansion of CMV-CTL obtained from G-CSF mobilized vs non-mobilized
PBMCs. Mean percentages of CD3 + CD8 + ST+ cells (b) and CD69+ or CD137+ cells (c) during culture
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percentage in the original sample. PBMCs were stimulated
with CMVpp65495–503 antigen to stimulate CMV-CTL
proliferation, expanded in the presence of IL-7 and IL-15,
and CMV-CTLs were finally isolated using ST. The func-
tion of the obtained cellular product was compared to iso-
lated directly from original PBMCs.
Following antigen-specific stimulation of G-CSF mobi-
lized PBMCs, CMV-CTL percentage increased from 1.62
% ± 2.42 at the beginning to 60.23 % ± 48.87 after 21 day
culture, with a mean fold increase of CMV-CTL subpop-
ulation of 361.85 (range 23.41 – 791.03). On the other
hand, CMV-CTL percentage in non-mobilized PBMCs
increased from 0.20 % ± 0.19 to 18.62 % ± 13.35 during
culture, and the absolute CMV-CTL number raised by
451.08 fold (range 7.73 – 794.73), similar to G-CSF mo-
bilized CMV-CTLs (Fig. 5a). CMV-specific T cell isola-
tion after expansion of G-CSF mobilized PBMCs showed
a mean purity and yield of 84.4 % ± 25.39 and 24.98 % ±
20.80, respectively. CMV-specific T cell isolation from
non-mobilized samples showed similar results, with amean purity of 98.67 % ± 0.25 and yield of 36.39 % ±
14.79 (Fig. 5b). Yield was slightly reduced when com-
pared to direct isolation of CMV-CTL from the original
PBMC samples.
In G-CSF mobilized samples, CD57 expression was
19.77 % ± 19.19 in original PBMCs, it was increased to
49.78 % ± 26.58 CD57+ by the end of the expansion, and
CVM-CTL isolated after culture were 53.57 % ± 29.75
CD57+. On the other hand, when non-mobilized sam-
ples were used, 17.22 % ± 9.90 CD57+ were present in
the original samples and the expression was increased to
67.31 % ± 6.07 at the end of the expansion, and after iso-
lation the CMV-CTL product expressed 72.47 % ± 19.49
CD57+. CD57 expression in the CMV-CTL product was
higher when compared to CMV-specific cells isolated
with ST directly from the original PBMCs, for both G-
CSF mobilized (9.72 % ± 7.75 CD57+) and non-mobilized
samples (9.50 % ±10.85). However, when directly isolated
CMV-CTL were afterwards expanded during 21 days,
the differences were lost (G-CSF mobilized CMV-CTL,
52.06 % ± 27.52 CD57+; non-mobilized CMV-CTL,
Fig. 3 Differentiation status of CMV-CTL in the original sample, after isolation and after expansion. (a) Mean CD57 expression of the CD3+ cells
was analyzed during in vitro culture in G-CSF mobilized (n = 3) and non-mobilized (n = 3) donor samples. Four subpopulations were distinguished
based on their CCR7 and CD45RA memory marker expression: TN, TCM, TEM and TEMRA. Percentage of the four differentiation stages was determined for
G-CSF mobilized (b) and non-mobilized (c) donor samples. They were analyzed in PBMCs before CMV-CTL isolation (n = 3), positive fraction of ST+
CMV-CTL isolation (n = 3) and CMV-CTL after 21 day expansion (n = 3)
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showed that, in both G-CSF mobilized (Fig. 5c) and
non-mobilized (Fig. 5d) donor samples, during culture
CMV-CTL TEMRA population decrease, that could denote
the poor proliferative capacity and senescence of late-
differentiated cells. Therefore, the CMV-CTL product
obtained was mainly formed of TEM cells (Table 2).
The functionality of cells isolated after antigen stimu-
lation and culture was similar to the product obtained
by direct selection and expansion (Table 3); after re-
stimulation with the antigen they re-expressed CD137
and CD69 activation markers (Fig. 5e) and produced
high levels of IFN-γ and granzyme B, lower levels of
TNF-α and IL-2, and undetectable levels of IL-10
(Fig. 5f ). It is important to mention that TNF-α and
granzyme B production by CMV-CTL isolated from G-
CSF mobilized samples is partly reduced when com-
pared to non-mobilized CMV-CTLs.Discussion
Adoptive transfer of CMV-specific T cell products gener-
ated from the original PBSC donor has shown promising
results in the field of cellular therapy [5, 17]. Most pro-
tocols have used non-mobilized apheresis samples as
starting material, but the manufacture of the therapeutic
product from the same G-CSF mobilized sample used
for PBSC collection offers great logistical and regulatory
advantages that could avoid the need for successive
blood donations and consequently widen the applicabil-
ity of the adoptive immunotherapy. Recently, the feasi-
bility of CMV-specific T cell generation from a G-CSF
mobilized collection has been assessed, confirming the
applicability of the procedure [6–8, 18]. Despite these
new findings, there is a concern about the effectiveness
of the generated cell products due to the immunosup-
pressive effects associated with G-CSF administration
[9, 19, 20]. Furthermore, it has been described that the
Table 1 Differentiation status of directly selected CMV-CTL
G-CSF mobilized Non-mobilized
TN TCM TEM TEMRA TN TCM TEM TEMRA
Before isolation 0.35 % ± 0.07 0.05 % ± 0.07 75.10 % ± 9.90 24.50 % ± 9.76 0.50 % ± 0.87 0.13 % ± 0.23 67.33 % ± 32.66 32.07 % ± 32.98
Positive Fraction 0.50 % ± 0.40 0.93 % ± 1.45 76.77 % ± 16.26 21.87 % ± 17.56 0.00 % ± 0.00 0.03 % ± 0.06 70.27 % ± 32.51 29.73 % ± 32.51
Expanded CMV-CTL 0.30 % ± 0.30 0.00 % ± 0.00 83.8 % ± 13.07 15.90 % ± 12.86 0.13 % ± 0.12 0.07 % ± 0.12 69.77 % ± 20.40 30.03 % ± 20.39
TN, TCM, TEM and TEMRA subpopulations were determined for G-CSF mobilized and non-mobilized samples in PBMCs before CMV-CTL isolation (n = 3), positive
fraction of ST+ CMV-CTL isolation (n = 3), and CMV-CTL after 21 day in vitro expansion (n = 3). Percentages were obtained from the CD3 + CD8 + ST+
cell subpopulation
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mobilized samples is higher compared to non-mobilized
sample staining [20], which would negatively affect the
isolation of CMV-CTLs. However, there are currently no
studies that evaluate virus-specific T cell production
from G-CSF mobilized samples by direct isolation with
MHC-multimers. In this study we have investigated
whether antigen-specific T cells can be efficiently iso-
lated from G-CSF mobilized samples using reversible
Streptamer technology and if T cell products manufac-
tured from mobilized PBMCs with this technology are
functionally competent and comparable to those ob-
tained from non-mobilized donors.Fig. 4 Marker expression and cytokine release after restimulation with antige
(n = 3) and non-mobilized (n = 3) PBMCs was analyzed by CD137 and CD6
after re-stimulation with CMVpp65-loaded PBMC (CMV feeders; CMV). (a) Mea
quantified from the CD3+ gate. (b) Surface marker expression in a representat
samples. (c) Intracellular cytokine staining (ICS) method was used to determin
and granzyme B (Granz B, Granzyme B). (d) Representative histograms of an IC
analysis of G-CSF mobilized and non-mobilized CMV-CTLs, with filled peaks shAfter direct CMV-specific T cell isolation from G-CSF
mobilized and non-mobilized samples using Streptamers,
CMV-CTLs were expanded in culture in order to obtain
sufficient cell numbers to perform functional assays. This
three week culture could reduce the negative effect of G-
CSF or the effect of G-CSF might be abrogated during the
expansion, but it was the only option we had to perform
functional assessment of isolated CMV-CTLs. CMV-
CTLs were dissociated from Streptamers and expanded by
co-culture with CMV-loaded autologous feeders and
homeostatic cytokines. Feeders were loaded with the
CMVpp65495–503 peptide since our group has previously
described that isolated cells are not able to persist in vitron. Functionality of expanded CMV-CTL obtained from G-CSF mobilized
9 expression quantification and cytokine production quantification
n CD137 and CD69 expression after CMV-loaded feeder re-stimulation,
ive re-challenge experiment for both non-mobilized and G-CSF mobilized
e the percentage of CD3+ cells that produced IFN-γ, IL-2, IL-10, TNF-α,
S experiment for the IFN-γ, IL-2, IL-10, TNF-α, and granzyme B production
owing matched isotype controls
Fig. 5 CMV-CTL production by prior stimulation, expansion, and subsequent isolation. CMV-CTL percentage in original PBMCs was increased by
peptide stimulation and cells were expanded during 21 days in the presence of IL-15 and IL-7. Afterwards, CMV-CTL were isolated using ST. The
process was carried out with non-mobilized (n = 3) and G-CSF mobilized (n = 3) PBMCs. (a) Representative histograms of a CMV-CTL expansion
and subsequent isolation. (b) Mean yield and purity of ST+ cell selection process for G-CSF mobilized and non-mobilized expanded PBMCs. Memory
phenotype of CMV-CTL obtained after isolation, from G-CSF mobilized (c) and non-mobilized (d) samples. Anti-viral function of isolated cells assessed
by activation marker expression (e) and cytokine production (f) upon peptide re-challenge
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data]. Accordingly, IL-7 and IL-15 were used due to their
importance for T cell homeostatic proliferation and sur-
vival [21, 22].
Although purity and yield of CMV-CTL isolation from
G-CSF mobilized donors was comparable to non-mobilized
PBMCs, the proliferative potential of cells obtained from
G-CSF mobilized PBMCs appeared to be reduced when
compared to non-mobilized samples when selected cells
were expanded in vitro. A possible explanation could be
that the tolerogenic effect induced by G-CSF administra-
tion could negatively affect the proliferation of CMV-CTLs
in vitro. However, when all PBMCs were stimulated withTable 2 Differentiation status CMV-CTL isolated after enrichment by
peptide
G-CSF mobilized
TN TCM TEM TEMRA
Before expansion 0.35 % ± 0.07 0.05 % ± 0.07 75.10 % ± 9.90 24.50 %
Expanded PBMCs 0.05 % ± 0.07 0.15 % ± 0.07 99.55 % ± 0.07 0.20 % ±
Positive fraction 0.00 % ± 0.00 0.10 % ± 0.14 99.70 % ± 0.14 0.15 % ±
TN, TCM, TEM and TEMRA subpopulations were determined for G-CSF mobilized and n
in vitro expansion (n = 3), and positive fraction of CMV-CTL isolation after culture (nthe antigen in order to induce CMV-CTL enrichment
before isolation, the expansion potential of CMV-specific
cells in G-CSF mobilized samples was comparable to non-
mobilized ones. We hypothesize that potential inadequa-
cies in the in vitro proliferation protocol resulted in
reduced proliferation of G-CSF mobilized CMV-CTLs and
that different culture conditions may improve proliferation.
Furthermore, in our previous studies where CMV-specific
T cells were isolated through CD25, CD137, or CD154 ac-
tivation marker expression and expanded in the same con-
ditions described here [6, 8, 18], cells isolated from G-CSF
mobilized PBMCs were able to proliferate as efficiently as
non-mobilized CMV-specific T cells. In these cases, thethree week expansion in the presence of CMVpp65495–503
Non-mobilized
TN TCM TEM TEMRA
± 9.76 0.50 % ± 0.87 0.13 % ± 0.23 67.33 % ± 32.66 32.07 % ± 32.98
0.14 0.17 % ± 0.29 0.03 % ± 0.06 90.87 % ± 11.52 8.97 % ± 11.23
0.07 0.00 % ± 0.00 0.10 % ± 0.10 96.70 % ± 3.32 3.20 % ± 3.39
on-mobilized samples in the original PBMC sample (n = 3), PBMCs after 21 day
= 3). Percentages were obtained from the CD3 + CD8 + ST+ cell subpopulation




CD137+ 84.50 % ± 0.42 81.20 % ± 3.54
CD69+ 92.00 % ± 9.33 94.10 % ± 1.98
CD137 + CD69+ 83.70 % ± 0.28 80.80 % ± 0.71
Cytokine production
IFN-γ 89.93 % ± 4.65 76.50 % ± 14.64
IL-2 0.61 % ± 0.56 1.91 % ± 1.30
IL-10 0.71 % ± 0.84 0.27 % ± 0.41
TNF-α 3.43 % ± 3.69 18.42 % ± 23.85
Granzyme B 55.83 % ± 28.36 92.07 % ± 2.28
Activation marker re-expression and cytokine production in response to antigenic
re-challenge was assessed in CMV-CTLs obtained from G-CSF mobilized (n = 3)
and non-mobilized (n = 3) PBMCs after 21 day expansion in the presence of the
peptide. Percentages were obtained from the CD3+ cell gate
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subsets. Therefore, the impaired expansion potential
described in this study could denote that G-CSF im-
munosuppression negatively affects CMV-specific CTL
but not helper T cell proliferation, or that isolated
antigen-specific CD8+ cells need CD4+ help in order to
overcome the immunosuppression exerted by G-CSF,
that could be related to the importance of CD4+ T cells
in the maintenance of a functional memory CD8+ T
cell pool [23]. Nevertheless, CMV-CTLs directly iso-
lated from G-CSF mobilized donor PBMCs may be able
to expand more efficiently in vivo, since the lymphope-
nic environment associated with HSCT is likely to be
favorable for T cell proliferation [24, 25], and could
help in overcoming the problems associated with our
proposed in vitro expansion protocol.
Differentiation status of CMV-CTLs was also assessed
during expansion. CD57 expression was analyzed, a
marker of functional immune senescence of T cells
that is associated with an impaired proliferation and
survival [26, 27]. It could be determined that CD57
expression is increased in both non-mobilized and
mobilized samples during expansion, reflecting that
CMV-CTL undergo several rounds of cell divisions.
Since it has been shown that both proliferative capacity
and survival of terminally differentiated CD8 + CD57+
donor T cells are limited following their transfer to HSCT
recipients [28], these data suggest that expanded CMV-
CTLs cells would potentially persist less in the recipient
compared to cells selected and directly infused into the
patient. By the end of the expansion, CD57 expression
in non-mobilized samples was higher than G-CSF mo-
bilized CMV-CTL, which correlates with the higher fold
expansion of non-mobilized CMV-CTLs observed during
culture.The differentiation status of the cells was further char-
acterized by analyzing the immunological phenotype of
CMV-CTLs using CD45RA and CCR7 memory markers
to distinguish between TN, TCM, TEM, and TEMRA sub-
populations [29]. CMV-CTL products, from both G-CSF
mobilized and non-mobilized samples were mainly com-
posed of TEM cells and a noteworthy proportion of
TEMRA cells, during all the studied stages. These results
correlate with the CD57 expression that characterizes
TEMRA cells and as well as proportion of TEM cells
[30, 31]. These TEM and TEMRA subpopulations which
accordingly express CD57+ maintain their proinflamma-
tory cytokine production capacity as well as high cytotoxic
effector properties, thereby conferring effective immediate
protection [32–34].
After expansion, specificity and effector function of
CMV-CTL obtained from both sample sources was ana-
lyzed following antigenic re-challenge. The vast majority
of cells in the cellular products expressed the TCR rec-
ognizing the CMVpp65495–503 peptide demonstrating
the high specificity of the product. At the beginning of
the expansion TCR suffered a downregulation following
the activation, which is known to be correlated with
antigen sensitivity [35]. A notable proportion of cells
expressed CD69 at the end of the expansion, which
could be related to the IL-15 present in the medium
[36], and upon antigen-specific stimulation a high pro-
portion of CD69+ cells accordingly re-expressed CD137.
Regarding cytokine production upon antigenic re-
stimulation, the majority of expanded CMV-CTL from
both G-CSF mobilized and non-mobilized samples re-
leased the pro-inflammatory cytokine IFN-γ, and lower
levels produced TNF-α and IL-2. No IL-10 secretion
was observed. This type 1 cytokine secretion profile
illustrates the anti-viral functionality of CMV-CTL gen-
erated in our protocol [35]. They also produced high
levels of the lytic molecule granzyme B, even prior to
antigenic re-stimulation, showing their cytotoxic ability
since it has been described how the preformation of
mature secretory lysosomes containing lytic proteins
correlates with the killing ability of cytotoxic cells [37].
This cytokine secretion pattern and granzyme B forma-
tion, together with their ability to express activation
markers such as CD137 and CD69, illustrates their abil-
ity to rapidly activate and induce an effective response
after encountering the antigen. Furthermore, it reveals
their capacity to confer an immediate effector function,
that correlates with the described effector memory T
cell phenotype [38].
For the clinical translation of this procedure, we would
first eliminate myeloid progenitors of G-CSF mobilized
samples performing the plastic adherent process, and
subsequently obtained cells would be frozen for storage.
When CMV-CTLs were needed, the cells would be thawed
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nology, since it has been previously described that CMV-
specific T cells can be isolated from frozen cells using
MHC-multimers and are totally functional when adminis-
tered in vivo [39].
Finally, we also analyzed an alternative method for the
generation of CMV-CTLs. In cases where detectable
CMV-CTL in the G-CSF mobilized sample is limited
and the purity of the obtained cell product could poten-
tially be reduced [40], CMV-CTL could be enriched in
the original sample by antigen-specific stimulation be-
fore isolation with the MHC-multimer. The cellular
product obtained with this alternative method main-
tained their functional activity and specificity, although
TNF-α and granzyme B production by G-CSF mobilized
CMV-CTL was slightly reduced if compared to non-
mobilized cells. CD57 expression in CMV-CTL increases
during culture, that could potentially impair their long-
term maintenance in vivo [28]. Furthermore, the cellular
product manufactured following antigenic stimulation
prior to direct selection would be considered an ATMP
with impact on associated regulatory issues and in-
creased costs. Therefore, even though this method
could be helpful for the isolation from samples with
low antigen-specific cell frequencies, our results do not
support it implementation.
Conclusions
Anti-viral product manufacture from the original G-CSF
mobilized PBSC graft offers great advantages mainly in
the unrelated donor setting, increasing the number of
patients that can benefit from this treatment. This, to-
gether with the straightforward CMV-specific T cell pro-
duction using GMP-grade Streptamers, enhances the
broad application into clinical routine of this therapy.
In this study we have been able to manufacture CMV-
specific CTLs from G-CSF mobilized donor samples
using Streptamer technology that present their anti-viral
function, determined by their high specificity and fast
and efficient response upon antigen-specific stimulation.
However, the capacity to generate pro-inflammatory cy-
tokines and lytic molecules was slightly reduced and
their proliferative potential was affected when compared
to non-mobilized cell products. Thus, whether the adop-
tive transfer of a CMV-CTL product from G-CSF mobi-
lized PBMCs can efficiently respond in vivo and control
CMV disease must be answered in future animal studies
and clinical trials.
Additional file
Additional file 1: Figure S1. Expansion and functionality of CMV-CTL
with or without ST dissociation. ST was dissociated (n = 3) or left
untouched (n = 3) from CMV-CTL isolated from non-mobilized samples,and cells were expanded and functionally characterized afterwards. (A)
Mean fold expansion of CMV-CTL obtained from non-mobilized samples,
with and without ST dissociation using D-biotin. Activation marker
expression (B) and cytokine production (C) upon antigenic re-stimulation in
expanded CMV-CTL with ST bound to the cell surface or ST dissociated from
the TCR.
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